AYTU

Aytu Biopharma Inc

2.120

+0.120+6.00%

After Hours: 2.119 -0.001 -0.05%19:30 09/18 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.000/2.000

TODAY RANGE2.000-2.170

VOL54.95K

MARKET CAP22.75M

52 WEEK RANGE1.650-3.065

AVG VOL (3M)26.05K

% TURNOVER0.51%

TURNOVER--

P/E (TTM)-0.4808

% RANGE7.50%

EPS(TTM)-4.4093

P/E(FORWARD)-1.5143

P/B0.6475

BVPS3.274

DIVIDEND--

P/S0.2867

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP20.85M

SHARES OUTSTANDING10.73M

NEXT EARNINGS09/21-09/25

FREE FLOAT9.84M

LOT SIZE1

EX-DATE01/06/2023

News

Press Releases

Financial Reports

Profile

NASDAQ·4d ago
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ·07/20 10:31
New Strong Sell Stocks for July 20th
NASDAQ·07/16 08:32
New Strong Sell Stocks for July 16th
Dow Jones·06/11 10:04
Aytu BioPharma Is Maintained at Buy by Ascendiant Capital
Dow Jones·06/11 10:04
Aytu BioPharma Price Target Raised to $14.50/Share From $14.00 by Ascendiant Capital
TipRanks·05/20 05:43
Aytu BioScience Bets on EXXUA Amid Legacy Declines
TipRanks·05/15 13:28
Aytu BioScience (AYTU) Gets a Buy from Maxim Group
TipRanks·05/15 00:31
Aytu BioScience Earnings Call: EXXUA Drives Transition
TipRanks·05/14 13:21
Lake Street Sticks to Its Buy Rating for Aytu BioScience (AYTU)
TipRanks·05/14 13:21
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)
Seeking Alpha·05/14 01:31
Aytu outlines $6M-$7M quarterly sales and marketing spend range as EXXUA scripts rise to over 920 in April
TipRanks·05/13 21:11
Aytu BioPharma reports Q3 EPS (53c), consensus (43c)
Seeking Alpha·05/13 14:00
Here are the major earnings after the close Wednesday
Seeking Alpha·05/12 21:35
Aytu BioPharma Q3 2026 Earnings Preview
TipRanks·04/02 20:44
Aytu BioScience Amends Warrants, Modifying Security Holder Rights

Same Industry

Name/Symbol

Change%

Price

AYTU

MCK

Biogen Inc

BIIB

-1.62%

215.50

AMGN

SHPG

CELG-RT

LLY

CELG

TXMD

JNJ

ABBV

ZTS

GILD

NVO

BMY

ALXN

PFE

SNY

GCVRZ

NVS

RDY

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.